Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases. Curza’s lead program (CZ-02) is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens, with a focus on drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome.